The SH2 domain-containing inositol 5-phosphatase SHIP1 is recruited to the intracytoplasmic domain of human Fc\gammaRIIB and is mandatory for negative regulation of B cell activation.

Isabelle Isnardi, Pierre Bruhns, Georges Bismuth, Wolf H Fridman, Marc Daëron

To cite this version:

Isabelle Isnardi, Pierre Bruhns, Georges Bismuth, Wolf H Fridman, Marc Daëron. The SH2 domain-containing inositol 5-phosphatase SHIP1 is recruited to the intracytoplasmic domain of human Fc\gammaRIIB and is mandatory for negative regulation of B cell activation.. Immunology Letters, Elsevier, 2006, 104 (1-2), pp.156-65. 10.1016/j.imlet.2005.11.027. pasteur-00270018

HAL Id: pasteur-00270018
https://hal-pasteur.archives-ouvertes.fr/pasteur-00270018

Submitted on 3 Apr 2008

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Title: The SH2 domain-containing inositol 5-phosphatase SHIP1 is recruited to the intracytoplasmic domain of human FcγRIIB and is mandatory for negative regulation of B cell activation.

Article Type: Research Article

Keywords: FcR, BCR, B cell, Negative regulation, Phosphatase, Signal Transduction

Abstract: Murine FcγRIIB were demonstrated to recruit SH2 domain-containing inositol 5-phosphatases (SHIP1/2), when their ITIM is tyrosyl-phosphorylated upon co-aggregation with BCR, and SHIP1 to account for FcγRIIB-dependent negative regulation of murine B cell activation. Although human FcγRIIB share the same ITIM as murine FcγRIIB and similarly inhibit human B cell activation, which among the four known SH2 domain-containing (tyrosine or inositol) phosphatases is/are recruited by human FcγRIIB is unclear. Our recent finding that, besides the ITIM, a second tyrosine-based motif is mandatory for murine FcγRIIB to recruit SHIP1 challenged the possibility that human FcγRIIB recruit this phosphatase. Human FcγRIIB indeed lack this motif. Using an experimental model which enabled us to compare human FcγRIIB and murine FcγRIIB under strictly controlled conditions, we show that SHIP1 is recruited to the intracytoplasmic domain of human FcγRIIB and inhibits the same biological responses and intracellular signals as when
recruited by murine FcγRIIB. Identical results were observed in murine and in human B cells. We demonstrate that SHIP is necessary for human FcγRIIB to inhibit BCR signaling, and cannot be replaced by SHP-1 or SHP-2. Although it contains no tyrosine, the C-terminal segment of human FcγRIIB was as mandatory as the tyrosine-containing C-terminal segment of murine FcγRIIB for SHIP1 to be recruited to the ITIM. This segment, however, did not recruit the adapters Grb2/Grap which were demonstrated to stabilize the recruitment of SHIP1 to the ITIM in murine FcγRIIB.
The SH2 domain-containing inositol 5-phosphatase SHIP1 is recruited to the intracytoplasmic domain of human FcγRIIB and is mandatory for negative regulation of B cell activation.

Isabelle Isnardi¹², Pierre Bruhns¹, Georges Bismuth³, Wolf H. Fridman² and Marc Daëron¹²,*

¹Unité d'Allergologie Moléculaire et Cellulaire, Département d'Immunologie, Institut Pasteur, 75015 Paris, France,
²Laboratoire d'Immunologie Cellulaire et Clinique, INSERM U.255, Institut de Recherches Biomédicales des Cordeliers, 75006 Paris, France,
³Laboratoire d'Immunopharmacologie Moléculaire, CNRS UPR 415, Institut Cochin de Génétique Moléculaire, 75 013 Paris, France.

*Corresponding author: Dr. Marc Daëron, Unité d'Allergologie Moléculaire et Cellulaire, Institut Pasteur, 25 rue du Docteur Roux, 75015 Paris, France. Tel : +33-1-4568-8642. Fax : +33-1-4061-3160. E-mail : daeron@pasteur.fr
Summary

Murine FcγRIIB were demonstrated to recruit SH2 domain-containing inositol 5-phosphatases (SHIP1/2), when their ITIM is tyrosyl-phosphorylated upon co-aggregation with BCR, and SHIP1 to account for FcγRIIB-dependent negative regulation of murine B cell activation. Although human FcγRIIB share the same ITIM as murine FcγRIIB and similarly inhibit human B cell activation, which among the four known SH2 domain-containing (tyrosine or inositol) phosphatases is/are recruited by human FcγRIIB is unclear. Our recent finding that, besides the ITIM, a second tyrosine-based motif is mandatory for murine FcγRIIB to recruit SHIP1 challenged the possibility that human FcγRIIB recruit this phosphatase. Human FcγRIIB indeed lack this motif. Using an experimental model which enabled us to compare human FcγRIIB and murine FcγRIIB under strictly controlled conditions, we show that SHIP1 is recruited to the intracytoplasmic domain of human FcγRIIB and inhibits the same biological responses and intracellular signals as when recruited by murine FcγRIIB. Identical results were observed in murine and in human B cells. We demonstrate that SHIP is necessary for human FcγRIIB to inhibit BCR signaling, and cannot be replaced by SHP-1 or SHP-2. Although it contains no tyrosine, the C-terminal segment of human FcγRIIB was as mandatory as the tyrosine-containing C-terminal segment of murine FcγRIIB for SHIP1 to be recruited to the ITIM. This segment, however, did not recruit the adapters Grb2/Grap which were demonstrated to stabilize the recruitment of SHIP1 to the ITIM in murine FcγRIIB.
Introduction

FcγRIIB are low-affinity receptors for the Fc portion of IgG, which were demonstrated to negatively regulate B Cell Receptor (BCR)-dependent B cell activation [1-3]. Confirming in vivo the inhibitory properties of FcγRIIB on B cell activation demonstrated in vitro, FcγRIIB-deficient mice were found to exhibit enhanced antibody responses [4], to be hyperresponsive to collagen-induced arthritis [5,6], and to develop spontaneous systemic lupus erythematosus when in the C57BL/6 background [7].

To exert their regulatory properties in B cells, FcγRIIB need to be coaggregated with BCR by IgG immune complexes [8]. Coaggregation enables FcγRIIB to be tyrosyl-phosphorylated [9] by the src kinases that are associated with BCR [10]. When phosphorylated, murine FcγRIIB recruit the single SH2 domain-containing inositol 5’-phosphatases SHIP1 [11,12] and SHIP2 [13]. Two tyrosine residues, contained in the intracytoplasmic domain of murine FcγRIIB, were found to be critical for the recruitment of SHIP1 [11,14]. One tyrosine is constitutive of an Immunoreceptor Tyrosine-based Inhibition Motif (ITIM) [15,16]. Due to the presence of two leucine residues at position Y+2 and Y+3, this motif specifically binds the SH2 domain of SHIP1 when phosphorylated [17]. It is mandatory for the recruitment of SHIP1 by murine FcγRIIB. We recently found that a second tyrosine-based motif, C-terminal to the ITIM, is also necessary for SHIP1 to be recruited by murine FcγRIIB. This motif binds the cytosolic adapters Grb2 and/or Grap which, by interacting with SHIP1 via their C-terminal SH3 domain, form a stable tri-molecular complex involving the receptor, the adapter and the phosphatase [14].

When recruited by FcγRIIB, SHIP1 is brought near the plasma membrane, where it can hydrolyze the 5-phosphate group in phosphatidylinositol-(3,4,5)-trisphosphate [PI(3,4,5)P3]. PI(3,4,5)P3, generated by phosphatidylinositol-3 Kinase following BCR
aggregation [18,19], provides docking sites for Pleckstrin Homology (PH) domain-containing molecules that critically contribute to BCR signaling. These include the Bruton’s Tyrosine Kinase (Btk) and Phospholipase C-γ (PLCγ) [20]. When phosphorylated by Btk [21] and by the tyrosine kinase Syk [22], PLCγ is activated and generates inositol-1,4,5-trisphosphate, which triggers the mobilization of intracellular Ca²⁺ stores and, secondarily, an influx of extracellular Ca²⁺. FcγRIIB-dependent inhibition of the Ca²⁺ response can therefore be accounted for by the catalytic activity of SHIP1. When recruited by FcγRIIB, SHIP1 becomes phosphorylated, and it also functions as an adaptor molecule. It indeed recruits the adapter molecule Dok1, which in turn recruits RasGAP, which enhances the autocatalytic GTPase activity of rasGTP and promotes a shift towards the rasGDP inactive form [23,24]. SHIP1 can therefore also inhibit the ras pathway independently of its phosphatase activity. Taken together, these results indicate that SHIP1 plays a central role in the inhibition of B cell responses by murine FcγRIIB. Supporting this conclusion, FcγRIIB-dependent inhibition of BCR-induced Ca²⁺ mobilization and Erk activation was markedly reduced in B cells from SHIP1-deficient mice [25,26].

Human FcγRIIB were also shown to inhibit both the Ca²⁺ response [27,28] and the ras pathway [3], when coaggregated with BCR in human B cells. Human FcγRIIB contain the same ITIM as murine FcγRIIB, which is likely to recruit SH2 domain-containing phosphatases when phosphorylated. Four SH2 domain-containing phosphatases have been described: the two protein tyrosine phosphatases SHP-1 and SHP-2, and the two inositol phosphatases, SHIP1 and SHIP2. Which, among these phosphatases, is/are responsible for human FcγRIIB-dependent negative regulation is unclear. Koncz et al. first reported the coprecipitation of SHP-2, but not that of SHIP1 or SHP-1 with human FcγRIIB, when coaggregated with BCR in human B cells [29], whereas Ehrhardt et al. reported the
coprecipitation of SHIP1, but not of SHP-1 or SHP-2 with human FcγRIIB expressed in murine B cells [30]. These studies were performed in different cells, as well as other studies which suggested a role for either protein tyrosine phosphatases or inositol phosphatases [31-33]. Our recent finding that a second tyrosine-based motif is mandatory for murine FcγRIIB to recruit SHIP1 made the possibility that human FcγRIIB could recruit this phosphatase unlikely. Although they contain an ITIM, human FcγRIIB indeed lack the C-terminal tyrosine-based motif.

To determine whether human FcγRIIB use different or the same phosphatases as murine FcγRIIB to inhibit B cell activation when coaggregated with BCR, we constructed chimeric receptors in which the intracytoplasmic domain of murine FcγRIIB had been replaced by the intracytoplasmic domain of human FcγRIIB. Wild-type murine FcγRIIB and murine-human chimeras were stably expressed in murine and in human B cells, and the responses of these cells were compared following coaggregation of recombinant receptors with endogenous BCR using the same extracellular ligands in the same cells. We found that the intracytoplasmic domain of human FcγRIIB triggers the same inhibitory signals as the intracytoplasmic domain of murine FcγRIIB and, surprisingly, that it selectively recruits SHIP1 in both murine and human B cells. The recruitment of SHIP1, however, also required the C-terminal segment of human FcγRIIB although no tyrosine is contained in this segment which did not recruit Grb2. Finally, we provide genetic evidence that SHIP1 is necessary for human FcγRIIB to negatively regulate B cell activation.
Materials and Methods

Cells. IIA1.6 cells were cultured in RPMI supplemented with 10% FCS, 100 IU/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine, 0.5 µM 2-mercaptoethanol and 2 mM sodium pyruvate. ST486 cells, a gift of Dr. G. Sarmay (Eötvös University, Budapest, Hungary) were cultured in OptiMEM supplemented with 10% FCS, 100 IU/ml penicillin, 100 µg/ml streptomycin and 2 mM L-glutamine. DT40 cells, purchased from Riken Cell Bank (Tsukuba Science City, Japan), were cultured in RPMI supplemented with 10% FCS, 1% chicken serum 100 IU/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine and 0.5 µM 2-mercaptoethanol.

Antibodies. The rat anti-mouse FcγRIIB 2.4G2 mAb [34] was purified on protein G-Sepharose. F(ab')2 fragments and IgG of polyclonal Rat anti-Mouse Ig (RatAM), F(ab')2 fragments and IgG of polyclonal Rabbit anti-Mouse Ig (RatAM), and IgG of polyclonal Rabbit anti-Chicken Ig (RatAC) were purchased from Jackson ImmunoResearch Laboratories (West Grove, PA), rabbit anti-phospho-Akt and anti-Akt antibodies and rabbit anti-phospho-Erk and anti-Erk antibodies from New England Biolabs (Beverly, MA), mouse anti-Grb2, mouse anti-SHP-1 and mouse anti-SHP-2 antibodies from Transduction Laboratories (Lexington, KY), mouse anti-phosphotyrosine mAbs (4G10), rabbit anti-SHIP1 from Upstate Biotechnology (Lake Placid, NY), HRP-conjugated Goat anti-Rabbit (HRP-GAR) and Goat anti-Mouse (HRP-GAM) Ig antibodies from Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit antibodies against recombinant EC domains of FcγRIIB were a gift from Pr. C. Sautès-Fridman (INSERM U255, Paris, France). Rabbit anti-human SHIP1 antibodies were a gift from Dr. S. Latour (INSERM U429, Paris, France). Rabbit anti-SHIP1 antibodies used in
DT40 cells were a gift from Dr. J. V. Ravetch (The Rockefeller University, New York, NY).

**cDNA constructs.** The cDNA of mouse FcγRIIB was modified by a point mutation of the codon coding for V212 (GTT->GTA), which induced no amino acid change, but created a KpnI restriction site. This cDNA encoding the extracellular and transmembrane domains and the six first intracytoplasmic amino acids of FcγRIIB was inserted into an expression vector under the control of the SRα promoter in pBR322 [35] and in which a neomycin-resistance or a zeocin-resistance gene was introduced. cDNAs encoding the intact or truncated intracellular domain of human, murine or chimeric FcγRIIB were amplified using the following primers.

B1mh: primer 1 (5’- GCC TTG GTA CCT CTC AGG AAA AAG CGG ATT-3’) and primer 2 (5’- ACA ATG GAG CTC AAA TAC GGT TCT GGT CAT-3’). B1mh Δ297: primer 1 and primer 3 (5’-CTC TTC CAG AGC TCC CTA GTG CAT GAG AAG-3’). B1mm Δ314 + hC-ter: primer 4 (5’- AAG AAA AAG CAG GTA CCA GCT CTC CCA-3’) and primer 5 (5’-CG AGC TCA AAT ACG GTT CTG GTC ATC AGG CTC TTC CAG AGC ATC CGG ATG CTT GAG AAG TGA GTA GGT-3’). These cDNAs were then fused to the cDNA encoding the extracellular and transmembrane domains of FcγRIIB. B1mm Δ314 was already described [36].

**Transfectants.** cDNAs were stably transfected in IIA1.6, ST486 and DT40 cells by electroporation. Transfectants were selected and cloned as described [37-39]. The expression of recombinant receptors was assessed by indirect immunofluorescence using the rat mAb 2.4G2 and Fluorescein Isothiocyanate-labeled F(ab’)2 fragments of Mouse anti-Rat Ig (FITC-MAR F(ab’)2) (Jackson ImmunoResearch). The expression of receptors on clones remained stable over the duration of experiments. Several clones of each transfectant were used and gave similar results.
**IL-2 secretion.** Aliquots of 5x10^5 IIA1.6 transfectants, resuspended in culture medium and distributed in 96-well microculture plates, were incubated with various concentrations of IgG or F(ab')2 RabAM for 18 h at 37°C. Cell-free supernatants were harvested and assayed for IL-2 on CTLL-2 cells as previously described [40].

**Flow cytometric analysis of Ca^{2+} mobilization.** Intracellular free Ca^{2+} concentration ([Ca^{2+}]_i) was determined by preloading 1x10^6 IIA1.6 or DT40 cells with 5 mM Fluo-3 AM (Molecular Probes, Eugene, OR) in the presence of 0.2 % Pluronic F-127 (Sigma Chemical Co., St. Louis, MO) for 30 min at room temperature. Cells were washed 3 times in RPMI, resuspended at 1x10^6 cells/ml in complete medium, and warmed for 3 min at 37°C before they were challenged with equimolar concentrations of intact or F(ab')2 fragments of anti-BCR antibodies. IIA1.6 cells were stimulated with 45 µg/ml RabAM IgG or 30 µg/ml RabAM F(ab')2. DT40 cells were stimulated with 135 µg/ml RabAC IgG or 90 µg/ml RabAC F(ab')2. Mean [Ca^{2+}]_i was monitored by flow cytometry using a FacsCalibur and calculated using the software FCS assistant 1.2.9 beta (Becton Dickinson).

**In vivo analysis of Akt translocation.** The construct encoding the Akt PH domain fused to enhanced Green Fluorescent Protein (GFP) was kindly provided by Dr. Tobias Meyer (Stanford University School of Medicine, Stanford, CA). Cells were transiently transfected with 5 µg of DNA by electroporation (280V, 960µF) and cultured for 16 h in complete culture medium before analysis. Fluorescence microscopy was performed with a Leitz DM IRB inverted microscope (Leica, Wetzlar, Germany) using a x100 oil objective on viable cells, seeded on glass coverslips placed in 30-mm Petri dishes. Cells were stimulated with 10 µg/ml RabAM F(ab')2 or 15 µg/ml RabAM IgG, and fluorescence was analyzed after a 10-min incubation at 37°C. Fluorescence images were collected with a cooled CDD camera.
(Micromax, Princeton Scientific Instruments, Inc, Monmouth Junction, NJ) and the Metamorph software (Universal Imaging Corporation, Downingtown, PA). For image processing and presentation, digital images (8 bits scale) were printed directly.

**Whole cell lysate analysis.** IIA1.6 and ST486 transfectants were stimulated at 37°C for the indicated times with 30 µg/ml intact or 20 µg/ml F(ab')2 fragments of RabAM IgG or RabAH IgG, and lysed by 3 cycles of incubation for 1 min in liquid nitrogen followed by 1 min at 37°C in lysis buffer pH 8.0 (50 mM Tris pH8, 150 mM NaCl, 1% Tx100, 1 mM Na3VO4, 5 mM NaF, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 10 µg/ml pepstatin and 1mM PMSF). Proteins were quantitated using a Biorad protein assay (Hercules, CA), and 40 µg proteins were treated as described in *Western blot analysis.*

**Immunoprecipitation.** IIA1.6 and ST486 transfectants were stimulated at 37°C for 3 min with 30 µg/ml RabAM IgG or RabAH IgG. Cells were lysed in lysis buffer pH 7.4 (10 mM Tris pH 7.4, 150 mM NaCl, 1% Tx100, 1 mM Na3VO4, 5 mM NaF, 5 mM Sodium pyrophosphate, 0.4 mM EDTA, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 10 µg/ml pepstatin and 1 mM PMSF). Postnuclear lysates were immunoprecipitated with 2.4G2-coated sepharose beads. Eluates from immunoadsorbents were treated as described in *Western blot analysis.*

**Western blot analysis.** Material was boiled in Sample Buffer, fractionated by SDS-PAGE and transferred onto Immobilon-P membranes (Millipore, Bedford, MA). Membranes were saturated with either 5% BSA (Sigma Chemical Co) or 5% skimmed milk (Régilait, Saint-Martin-Belle-Roche, France) diluted in Western buffer (150 mM NaCl, 10 mM Tris and 0.5% Tween 20 (Merk, Schuchardt, Germany) pH7.4), and incubated with the indicated antibodies followed by HRP-GAR or HRP-GAM. Labeled antibodies were detected using an ECL kit (Amersham Pharmacia biotech, Little Chalfont, Buckinghamshire).
Results

A chimeric receptor containing the intracytoplasmic domain of human FcγRIIB inhibits BCR signaling in murine B cells.

Chimeric receptors, containing the extracellular and transmembrane domains of murine FcγRIIB and the intracytoplasmic domain of human FcγRIIB1 (B1mh) were constructed and stably expressed in the FcγR-deficient variant of the murine B lymphoma A20/2J, IIA1.6. Wild-type (B1mm) and intracytoplasmic domain-deleted (B1m) murine FcγRIIB1 expressed in the same cells were used as positive and negative controls, respectively (Fig. 1). BCR were either aggregated using rabbit anti-mouse Ig (RabAM) F(ab')2 fragments, or coaggregated with FcγRIIB using intact RabAM IgG antibodies, and FcγRIIB-dependent inhibition was assessed by comparing biological responses and intracellular signals elicited in IIA1.6 cells under these two conditions.

B1mh abolished BCR-dependent IL-2 secretion as efficiently as B1mm, but not B1m (Fig. 2A). B1mh inhibited the late phase of the BCR-dependent Ca\(^{2+}\) response as efficiently as B1mm, but not B1m (Fig. 2B). B1mh inhibited BCR-dependent phosphorylation of the MAP Kinases Erk1/2 as efficiently as B1mm, but not B1m (Fig. 2C). B1mh, B1mm or B1m, however, did not detectably decrease BCR-dependent tyrosyl-phosphorylation of proteins in whole cell lysates (not shown).

We next examined signaling events that depend on the generation of membrane phospholipids. Akt is phosphorylated by PDK1 [41] when both molecules are translocated to the membrane via the interaction of their PH domain with PI(3,4,5)P3 or PI(4,5)P2. Akt phosphorylation was induced with similar intensities in the three transfectants upon BCR aggregation. It was inhibited when BCR were coaggregated with B1mh and B1mm, but not
with B1m (Fig. 2D). To assess more directly membrane PI(3,4,5)P3, a GFP construct containing the PH domain of Akt was transiently expressed in the three transfectants. GFP had a diffuse cytosolic distribution in unstimulated cells. It was translocated to the membrane upon BCR aggregation. This translocation was prevented when BCR were coaggregated with either B1mh or B1mm, but not with B1m (Fig. 2E).

These results altogether indicate that chimeric receptors containing the intracytoplasmic domain of human FcγRIIB1 can inhibit BCR-dependent cytokine secretion, Ca²⁺ response, ras pathway activation, membrane translocation and phosphorylation of Akt as efficiently as murine FcγRIIB1, without affecting the overall intracellular protein phosphorylation.

**SHIP1 is recruited to the intracytoplasmic domain of human FcγRIIB1 in murine and in human B cells.**

To identify phosphatases possibly recruited by human FcγRIIB, B1mh and B1mm were coaggregated with BCR by RabAM IgG antibodies in IIA1.6 transfectants, and immunoprecipitated using the same anti-murine FcγRIIB mAb. B1mh was tyrosyl-phosphorylated when coaggregated with BCR, albeit to a lower extent than B1mm. SHIP1, but neither SHP-1 nor SHP-2, coprecipitated with B1mh and, as expected, with B1mm. Noticeably, comparable amounts of SHIP1 coprecipitated with B1mm and B1mh, in spite of the lower phosphorylation of the latter (Fig. 3A).

To exclude that B1mh behaved like B1mm because they were expressed in murine cells, the same two constructs were stably expressed in ST486, a human B lymphoma cell line that lacks endogenous FcγR. ST486 clones expressing comparable amounts of recombinant receptors were selected (Fig. 1). B1mh and B1mm were coaggregated with BCR using rabbit
anti-human Ig (RabAH) IgG antibodies. Under these conditions, B1mh was, again, less phosphorylated than B1mm, and SHIP1, but neither SHP-1 nor SHP-2, coprecipitated with both B1mh and B1mm in ST486 cells (Fig. 3B).

A chimeric receptor containing the intracytoplasmic domain of human FcRIIB therefore recruited SHIP1 selectively, when tyrosyl-phosphorylated upon coaggregation with BCR, in both murine and human B cells.

The recruitment of SHIP1 requires the 13 C-terminal amino acids in the intracytoplasmic domain of human FcγRIIB.

We recently demonstrated that, in addition to the ITIM, a second tyrosine-based motif is required for murine FcγRIIB1 to recruit SHIP1 [14]. This second motif, C-terminal to the ITIM, is conserved in all three isoforms of murine FcγRIIB, but not in the two isoforms of human FcγRIIB. We investigated whether, although it contains no tyrosine, the C-terminal segment of the intracytoplasmic domain of human FcγRIIB, could play the same role as the tyrosine-containing C-terminal segment of the intracytoplasmic domain of murine FcγRIIB.

B1mh chimeras deleted of their 13 C-terminal intracytoplasmic amino acids (B1mh Δ297) were constructed and expressed in IIA1.6 cells. These receptors were compared with murine FcγRIIB1 deleted of the 16 C-terminal intracytoplasmic amino acids (B1mm Δ314) expressed in the same cells (Fig. 1). Non-deleted B1mh and B1mm served as positive controls. As previously observed [36], SHIP1 failed to coprecipitate with B1mm Δ314, which was phosphorylated upon coaggregation with BCR. SHIP1 also failed to coprecipitate with B1mh Δ297, which was tyrosyl-phosphorylated under the same conditions (Fig. 4). Although they contain no tyrosine, the 13 C-terminal amino acids of the intracytoplasmic domain of human FcγRIIB are therefore necessary for these receptors to recruit SHIP1.
To investigate their role in the recruitment of SHIP1, the 13 C-terminal aminoacids of human FcγRIIB were used to replace the tyrosine-containing C-terminal 16 aminoacids that were deleted in B1mm Δ314. The resulting chimera (B1mm Δ314+hCter) was expressed in IIA1.6 cells (Fig. 1) and coaggregated with BCR. SHIP1 coprecipitated with tyrosyl-phosphorylated B1mm Δ314+hCter (Fig. 4). The 13 C-terminal aminoacids of human FcγRIIB could therefore restore the ability of B1mm Δ314 to recruit SHIP1. B1mh, however, lacks the C-terminal tyrosine-based motif which we demonstrated to recruit Grb2 [14], and, as expected, Grb2 failed to coprecipitate with B1mh, when the latter was coaggregated with BCR in IIA1.6 cells (Fig. 4). Supporting this observation, a 13-aminoacid phosphorylated synthetic peptide corresponding to the 13 C-terminal aminoacids of human FcγRIIB failed to bind Grb2 when incubated in IIA1.6 cell lysates (data not shown). It also failed to bind SHIP1.

Altogether, these results indicate that, like the intracytoplasmic domain of murine FcγRIIB, the intracytoplasmic domain of human FcγRIIB requires a C-terminal sequence, in addition to the ITIM, to recruit SHIP1. The mechanism by which their C-terminal sequence enables human FcγRIIB to recruit SHIP1 is however different from the mechanism by which their C-terminal sequence enables murine FcγRIIB to recruit SHIP1.

SHIP1 is mandatory for inhibition of BCR-dependent B cell activation by human FcγRIIB1.

SHIP1 being selectively coprecipitated with B1mh, we investigated whether this phosphatase is necessary for human FcγRIIB to inhibit BCR-dependent B cell activation. Since both SHIP1 and SHP-2 were reported to coprecipitate with human FcγRIIB [29,30], B1mh and B1mm were expressed in wild-type, SHIP-deficient, or SHP-2-deficient DT40...
chicken B cells. BCR aggregation, induced by F(ab’)_2 fragments of rabbit anti-chicken Ig (R\textsubscript{abAC}) antibodies, increased the intracellular Ca\textsuperscript{2+} concentration in all three DT40 transfectants. As expected, the Ca\textsuperscript{2+} response was shortened when BCR were coaggregated with either B1mh or B1mm by intact R\textsubscript{abAC} IgG in wild-type DT40 cells. B1mm-induced inhibition of the Ca\textsuperscript{2+} response was abrogated in SHIP-deficient cells, as previously described, but not in SHP-2-deficient cells. B1mh-induced inhibition of the Ca\textsuperscript{2+} response was also abrogated in SHIP-deficient cells, but not in SHP-2-deficient cells (Fig. 5). SHIP1 is therefore necessary not only for murine Fc\textgamma RIIB-, but also for human Fc\textgamma RIIB-dependent inhibition of BCR signaling.

**Discussion**

We document here the molecular mechanism by which human Fc\textgamma RIIB inhibit BCR signaling. We found that the SH2 domain-containing inositol 5-phosphatase SHIP1 is recruited to the intracytoplasmic domain of human Fc\textgamma RIIB and inhibits the same biological responses and intracellular signals as when recruited by murine Fc\textgamma RIIB. We show that SHIP is necessary not only for murine, but also for human Fc\textgamma RIIB to inhibit BCR signaling, and cannot be replaced by SHP-1 or SHP-2. The mechanism that enables human and murine Fc\textgamma RIIB to recruit SHIP1 is however different.

The first ITIM was identified as a highly conserved tyrosine-containing sequence, when comparing the intracytoplasmic domains of murine and human Fc\textgamma RIIB which had been found to exert comparable inhibitory properties on cell activation by ITAM-containing receptors [42]. Phosphorylated peptides corresponding to this sequence were found to bind in \textit{vitro} the four known SH2 domain-containing phosphatases when immobilized on beads and incubated in murine [15] or in human [29,31] cell lysates. Although initially reported to
recruit SHP-1 [15], murine FcγRIIB was convincingly shown to selectively recruit SHIP1 when co-engaged with BCR in B cells or with FcεRI in mast cells [11,12,43,44]. Discordant results were reported by several groups who investigated the recruitment of phosphatases by human FcγRIIB. Several reasons may explain these inconsistencies. No mAb specific for human FcγRIIB is available, and human B cells express not only FcγRIIB, but also ITAM-containing FcγRIIA. The extracellular domains of the two receptors being highly conserved, both FcγRIIB and FcγRIIA are co-aggregated with BCR when engaged by IgG immune complexes or by intact IgG anti-human Ig on human B cells. Available mAbs also precipitate less efficiently human FcγRIIB, compared to murine FcγRIIB. In addition, human FcγRIIB is less tyrosyl-phosphorylated than murine FcγRIIB, when co-aggregated with BCR. The intracytoplasmic domain of human FcγRIIB1 indeed contains two tyrosines only, whereas that of murine FcγRIIB1 contains four tyrosines. Finally, different cell types and different experimental conditions were used by different groups who did not always distinguish the \textit{in vitro} binding of phosphatases to phospho-peptides, the \textit{in vivo} coprecipitation of phosphatases with FcγRIIB in pervanadate-treated cells, and the \textit{in vivo} coprecipitation of phosphatases with FcγRIIB when co-aggregated with BCR. In order to overcome these difficulties, we generated an experimental model which enabled us to compare human FcγRIIB and murine FcγRIIB under strictly controlled conditions. Clones of transfectants expressing comparable levels of murine FcγRIIB1 (B1mm), murine-human chimeric FcγRIIB1 (B1mh) or tail-less murine FcγRIIB (B1m) could be selected using the same mAb to assess receptor expression. B1mm and B1mh could be both expressed and compared in the same cells \textit{i.e.} in murine B cells, in human B cells or in chicken B cells which otherwise express no other FcγR. The same extracellular ligands could be used to co-aggregate BCR with B1mm and B1mh, and the
same biological responses could be examined in each B cell type. Finally, the same antibodies could be used to precipitate B1mm and B1mh with the same efficiency in all B cells.

Using this experimental model, we found that SHIP1 is the effector of human FcγRIIB-dependent negative regulation of B cell activation. First of all, B1mm and B1mh comparably inhibited BCR-dependent IL-2 secretion and major signaling events, including MAP kinase activation, Ca²⁺ mobilization, Akt phosphorylation and PI(3,4,5)P3 generation, as assessed by the translocation of a GFP-PHAkt construct, in murine B cells. Second, SHIP1 similarly coprecipitated with B1mm and B1mh, when tyrosyl-phosphorylated upon co-aggregation with BCR. Identical results were observed in IIA1.6 and in ST486 cells, excluding that murine and human FcγRIIB could function differently in murine and human B cells, respectively. Our results are consistent with previous papers reporting that SHIP1 was recruited by human FcγRIIB in IIA1.6 cells [30], and that inhibition of FcγRIIA-mediated phagocytosis observed upon coaggregation with human FcγRIIB was enhanced in COS cells overexpressing SHIP1 [33]. Noticeably, neither SHP-1 nor SHP-2 coprecipitated with B1mh when coaggregated with BCR in IIA1.6 or in ST486 cells. SHP-2 was previously described to coprecipitate with human FcγRIIB in a human B cell line [29] and in melanoma cells treated with pervanadate [45]. Likewise, SHP-1 coprecipitated with murine FcγRIIB in pervanadate-treated B cells, but not following coaggregation with BCR [44]. Finally, the deletion of SHIP abrogated the inhibition of Ca²⁺ mobilization by both B1mm and B1mh in DT40 cells. SHIP, but not SHP-2, is therefore used by and mandatory for human FcγRIIB to inhibit BCR signaling. Supporting this conclusion, no major alteration of the pattern of tyrosyl-phosphorylation was observed in whole cell lysates following BCR aggregation or following the co-aggregation of BCR with B1mm or B1mh in IIA1.6 cells.

Our experimental model also enabled us to show that, like for murine FcγRIIB, the
ITIM is not sufficient for enabling human FcγRIIB to recruit SHIP1. Their C-terminal segment is indeed necessary for both receptors to recruit the phosphatase. Different mechanisms, however, stabilize the binding of SHIP1 to the ITIM in human and murine FcγRIIB. We have recently shown that SHIP1 needs the cooperation of the cytosolic adapters Grb2 and/or Grap in order to be recruited by murine FcγRIIB. These adapters are recruited to a second tyrosine-containing motif, located C-terminal to the ITIM in the intracytoplasmic domain of FcγRIIB [14]. This finding was puzzling as human FcγRIIB contain the same ITIM as murine FcγRIIB, but they lack this second motif in their C-terminal segment. Another tyrosine, located N-terminal to the ITIM, in human FcγRIIB1 could have possibly played the same role, in human FcγRIIB, as that played by the C-terminal motif in murine FcγRIIB. A point mutation of this tyrosine, however, did not impair the ability of human FcγRIIB1 to inhibit BCR-induced Ca\textsuperscript{2+} mobilization [46]. Surprisingly, the deletion of their 13 C-terminal amino acids made B1mh unable to detectably coprecipitate SHIP1. The contribution of these amino acids to the recruitment of SHIP1 was formally demonstrated by replacing the tyrosine-containing C-terminal segment of murine FcγRIIB by the C-terminal segment of human FcγRIIB. This substitution indeed restored the ability of the murine FcγRIIB deletant to recruit SHIP1, but not Grb2. Although it contains no tyrosine, the C-terminal segment of human FcγRIIB therefore plays the same role as the C-terminal segment of murine FcγRIIB. How it stabilizes the recruitment of SHIP1 is unknown. As a synthetic peptide corresponding to this segment failed to bind SHIP1 \textit{in vitro}, the simplest possibility is that it recruits another molecule that can also bind to SHIP1. We however failed to coprecipitate any of the previously described binding partners of SHIP1 with B1mh, and no additional band was observed in silver-stained B1mh immunoprecipitates, when compared with B1mm immunoprecipitates in IIA1.6 cells (not shown). If one aligns residues in the C-terminal
segments of murine and human FcγRIIB, one observes that 10 of 13 amino acids are identical or similar. Putative molecules that could interact both with this sequence in human FcγRIIB and with SHIP1 remain to be identified.

In conclusion, this work demonstrates that SHIP1 is the effector of the inhibition of B cell activation by human FcγRIIB, when recruited to the phosphorylated ITIM and stabilized by the C-terminal segment through an unknown molecular interaction. Interestingly, the expression of SHIP1 is highly regulated in hematopoietic cells. Thus, SHIP1 expression was reported to be high in immature B cells and to decrease as cell differentiate into mature B cells [47]. FcγRIIB-dependent negative regulation of cell activation may therefore vary as human B cells mature and differentiate. Whether abnormally high or low levels of SHIP1 are associated with pathological conditions involving defects in FcγRIIB-dependent negative regulation is an interesting possibility to investigate.
References


Acknowledgments
We are grateful to Dr. Gabriella Sarmay (Eötvös University, Budapest, Hungary) for ST486 cells, Pr. Catherine Sautès-Fridman (INSERM U255, Paris, France) for anti-FcγRIIB antibodies, Dr. Sylvain Latour (INSERM U429, Paris, France) for anti-human SHIP1, Dr. Jeffrey V. Ravetch (The Rockefeller University, New York, NY) for anti-SHIP1 antibodies used for DT40 cells and Dr Tobias Meyer (Stanford University School of Medicine, Stanford, CA) for the GFP-Akt PH construct. This work was supported by institutional grants from the INSERM, the Institut Pasteur and the Université Pierre et Marie Curie. I.I. was supported by a fellowship from the Université Pierre et Marie Curie.
Figure Legends:

Figure 1. Recombinant receptors and chimeras used in this study. Receptors and receptor segments of murine (m) and human (h) origin are represented in white and black, respectively. The ITIM, conserved in murine and human FcγRIIB, is shown as a gray box. The expression of recombinant molecules in IIA1.6 and in ST486 cells was assessed by indirect immunofluorescence using the rat mAb anti-murine FcγRIIB extracellular domain 2.4G2 and FITC-MAR F(ab’2). Thin histograms, FITC-MAR F(ab’2) only; thick histograms, 2.4G2 followed by FITC-MAR F(ab’2).

Figure 2. B1mh inhibits IL-2 secretion, Ca^{2+} mobilization, Erk phosphorylation, Akt phosphorylation and Akt membrane translocation in IIA1.6 cells. (A) Inhibition of BCR-dependent IL-2 secretion. IIA1.6 transfectants were stimulated with indicated concentrations of R_{ab}AM F(ab’2) (open circles) or R_{ab}AM IgG (closed circles). IL-2 released in 18-h culture supernatants was assayed for[^3]H]thymidine incorporation in CTLL-2 cells. The figure represents the radioactivity incorporated in CTLL-2 cells as a function of the concentration of R_{ab}AM F(ab’2) or IgG. (B) Inhibition of BCR-dependent Ca^{2+} mobilization. IIA1.6 transfectants were loaded with Fluo-3, stimulated with either R_{ab}AM F(ab’2) (grey line) or R_{ab}AM IgG (black line) at the time indicated by the arrow, and intracellular Ca^{2+} concentration was monitored by flow cytometry. (C) Inhibition of BCR dependent Erk phosphorylation. IIA1.6 transfectants were unstimulated (-) or stimulated (+) with either R_{ab}AM F(ab’2) or R_{ab}AM IgG for the indicated periods of time. Cells were lysed, and proteins were fractionated by SDS-PAGE and Western blotted with anti-pErk or anti-Erk antibodies. (D) Inhibition of BCR-dependent Akt phosphorylation. IIA1.6 transfectants were unstimulated...
(-) or stimulated (+) with either RatAM F(ab’)2 or RatAM IgG for the indicated periods of time. Cells were lysed, and proteins were fractionated by SDS-PAGE and Western blotted with anti-pAkt or anti-Akt antibodies. (E) Inhibition of BCR-dependent Akt translocation. IIA1.6 transfectants were transiently transfected with a cDNA construct encoding a fusion protein composed of the Akt PH domain linked to GFP. Cells were unstimulated (medium) or stimulated with either RatAM F(ab’)2 or RatAM IgG for 10 min.

**Figure 3. B1mh recruits SHIP1 in murine and in human B cells.** (A) Coprecipitation of phosphatases in IIA1.6 cells. IIA1.6 transfectants were stimulated (+) or not (-) with RatAM IgG for 3 min. Cells were lysed and FcγRIIB were precipitated. Immunoprecipitates were fractionated by SDS-PAGE and Western blotted with anti-FcγRIIB, anti-pTyr, anti-SHIP1, anti-SHP-1 and anti-SHP-2 antibodies. (B) Coprecipitation of phosphatases in ST486 cells. ST486 transfectants were stimulated (+) or not (-) with Rabbit IgG for 3 min. Cells were lysed and FcγRIIB were precipitated. Immunoprecipitates were fractionated by SDS-PAGE and Western blotted with anti-FcγRIIB, anti-pTyr, anti-SHIP1, anti-SHP-1 and anti-SHP-2 antibodies.

**Figure 4. The C-terminal segment of the intracytoplasmic domain of human FcγRIIB is necessary for SHIP1 to coprecipitate with B1mh.** IIA1.6 transfectants were stimulated (+) or not (-) with RatAM IgG for 3 min. Cells were lysed and FcγRIIB were precipitated. Immunoprecipitates were fractionated by SDS-PAGE and Western blotted with anti-FcγRIIB, anti-pTyr, anti-SHIP1 and anti-Grb2 antibodies.

**Figure 5. SHIP is mandatory for B1mh-dependent inhibition of Ca^{2+} mobilization in**
**DT40 cells.** B1mm and B1mh were expressed in wt, SHIP^+/− and SHP-2^+/− DT40 cells. The expression of recombinant receptors in the three types of DT40 cells was assessed by indirect immunofluorescence using 2.4G2 and FITC-MAR F(ab′)2. Thin histograms, FITC-MAR F(ab′)2 only; thick histograms, 2.4G2 and FITC-MAR F(ab′)2. W.t., SHIP^+/− and SHP-2^+/− DT40 transfectants were loaded with Fluo-3, stimulated with either RabAC F(ab′)2 (grey line) or RabAC IgG (black line) at the time indicated by the arrow, and intracellular Ca^{2+} concentration was measured.
Figures 1, 3, 4 & 5

Recombinant receptors and chimeras used in this study

IIA1.6
ST486
murine
Fcγγγγ RIIB1
Y    ... 100 102 104 100 102 104 100 102 104 101 103 101 103 101 103 101 103 101 103 101 103
100 102 101 103 104 100 102 101 103 104

Fig. 1
Recombinant receptors and chimeras used in this study
IIA1.6
ST486
murine
Fcγγγγ RIIB1
Y    ... 100 102 104 100 102 104 100 102 104 101 103 101 103 101 103 101 103 101 103 101 103 101 103
100 102 101 103 104 100 102 101 103 104

Figures 1, 3, 4 & 5
Hal-Pasteur author manuscript  pasteur-00270018, version 1

Fig. 1
Fig. 3

A

IIA1.6

<table>
<thead>
<tr>
<th></th>
<th>B1mh</th>
<th>B1mm</th>
</tr>
</thead>
<tbody>
<tr>
<td>IgG</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>52</td>
<td></td>
<td></td>
</tr>
<tr>
<td>WB: anti-FcγRIIB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>WB: anti-pTyr</td>
<td></td>
<td></td>
</tr>
<tr>
<td>WB: anti-SHPI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>WB: anti-SHP-2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>WB: anti-SHP-1</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B

ST486

<table>
<thead>
<tr>
<th></th>
<th>B1mh</th>
<th>B1mm</th>
</tr>
</thead>
<tbody>
<tr>
<td>IgG</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>52</td>
<td></td>
<td></td>
</tr>
<tr>
<td>WB: anti-FcγRIIB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>WB: anti-pTyr</td>
<td></td>
<td></td>
</tr>
<tr>
<td>WB: anti-SHPI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>WB: anti-SHP-2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>WB: anti-SHP-1</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Fig. 4

<table>
<thead>
<tr>
<th></th>
<th>B1mh</th>
<th>B1mm</th>
<th>B1mhΔ297</th>
<th>B1mmΔ314</th>
<th>B1mmΔ314 + hCter</th>
</tr>
</thead>
<tbody>
<tr>
<td>RgAM IgG</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>WB: anti-FcγRIIB</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WB: anti-pTyr</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WB: anti-SHIP1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WB: anti-Grb2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Fig. 5

<table>
<thead>
<tr>
<th>Wild-type</th>
<th>SHIP-/-</th>
<th>SHP-2-/-</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>B1mm</td>
<td>B1mh</td>
</tr>
<tr>
<td>Relative Cell numbers</td>
<td>![Graph]</td>
<td>![Graph]</td>
</tr>
<tr>
<td>Relative fluorescence intensity</td>
<td>![Graph]</td>
<td>![Graph]</td>
</tr>
</tbody>
</table>

Time (s)
Relative fluorescence intensity

Fig. 5
Paris, November 21, 2005

Dear Vaclav,

The electronic system requests a cover letter. Here it is.
The quality of the pdf version of Fig. 2 being very poor, I have attached a better version.
Please, use it.
Thanks for taking care of our manuscript.
Best regards,
Marc

Marc Daëron, MD, PhD,
Directeur de Recherche à l’INSERM
Chef d’Unité à l’Institut Pasteur
Response to reviewer

Required changes have been made.